T cell adjuvants and novel strategies for their identification

Immunopotentiators in Modern Vaccines

Volumn , Issue , 2005, Pages 275-288

  Van Overvelt, Laurence ^a   Moingeon, Philippe ^a  

^a Stallergenes SA   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33646413471     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012088403-2/50017-4     Document Type: Chapter

References (185)

1. A.K. Abbas, K.M. Murphy and A. Sher (1996) Functional diversity of helper T lymphocytes. Nature 383 787-793.
2. T. Aguado, H. Engers, T. Pang and R. Pink (1999) Novel adjuvants currently in clinical testing: November 2–4, 1998, Fondation Mérieux, Annecy, France. A meeting sponsored, by the World Health Organization. Vaccine 17 2321-2328.
3. O. Akbari, G.J. Freeman, E.H. Meyer, E.A. Greenfield, T.T. Chang, A.H. Sharpe, G. Berry, R.H. DeKruyff and D.T. Umetsu (2002) Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. Nature Med. 8 1024-1032.
4. O. Akbari, P. Stock, R.H. DeKruyff and D.T. Umetsu (2003) Role of regulatory T cells in allergy and asthma. Curr. Opin. Immunol. 15 627-633.
5. F.J. Barrat, D.J. Cua, A. Boonstra, D.F. Richards, C. Crain, H.F. Savelkoul, R. de Waal-Malefyt, R.L. Coffman, C.M. Hawrylowicz and A. O'Garra (2002) In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J. Exp. Med. 195 603-616.
6. F. Belardelli, M. Ferrantini, G. Parmiani, J. Schlom and E. Garaci (2004) International meeting on cancer vaccines: how can we enhance efficacy of therapeutic vaccines? Cancer Res. 64 6827-6830.
7. A. Bendelac, M. Bonneville and J.F. Kearney (2001) Autoreactivity by design: innate B and T lymphocytes. Nature Rev. Immunol. 1 177-186.
8. J.A. Berzofsky, J.D. Ahlers and I.M. Belyakov (2001) Strategies for designing and optimizing new generation vaccines. Nature Rev. Immunol. 1 209-219.
9. M.C. Bonnet, J. Tartaglia, F. Verdier, P. Kourilsky, A. Lindberg, M. Klein and P. Moingeon (2000) Recombinant viruses as a tool for therapeutic vaccination against human cancers. Immunol. Lett. 74 11-25.
10. V.A. Boussiotis, E.Y. Tsai, E.J. Yunis, S. Thim, J.C. Delgado, C.C. Dascher, A. Berezovskaya, D. Rousset, J.M. Reynes and A.E. Goldfeld (2000) IL-10-producing T cells suppress immune responses in anergic tuberculosis patients. J. Clin. Invest. 105 1317-1325.
11. N. Burdin and M. Kronenberg (1999) CD1-mediated immune responses to glycolipids. Curr. Opin. Immunol. 11 326-331.
12. N. Burdin, B. Guy and P. Moingeon (2004) Immunological foundations to the quest for new vaccine adjuvants. Biodrugs 18 79-93.
13. I. Caramalho, T. Lopes-Carvalho, D. Ostler, S. Zelenay, M. Haury and J. Demengeot (2003) Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide. J. Exp. Med. 197 403-411.
14. S.R. Carding and P.J. Egan (2002) Gamma delta T cells: functional plasticity and heterogeneity. Nature Rev. Immunol. 2 336-345.
15. L.L. Carter and R.W. Dutton (1996) Type 1 and type 2: a fundamental dichotomy for all T cell subsets. Curr. Opin. Immunol. 8 336-342.
16. W. Chen, W. Jin, N. Hardegen, K.J. Lei, L. Li, N. Marinos, G. McGrady and S.M. Wahl (2003) Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med. 198 1875-1886.
17. D.N. Cook, D.S. Pisetsky and D.A. Schwartz (2004) Toll-like receptors in the pathogenesis of human disease. Nature Immunol. 5 975-979.
18. P.G. Coulie, V. Karanikas, D. Colau, C. Lurquin, C. Landry, M. Marchand, T. Dorval, V. Brichard and T. Boon (2001) A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc. Natl. Acad. Sci. USA 98 10290-10295.
19. E.C. De Jong, P.L. Vieira, P. Kalinski, J.H. Schuitemaker, Y. Tanaka, E.A. Wierenga, M. Yazdanbakhsh and M.L. Kapsenberg (2002) Microbial compounds selectively induce Th1 cell-promoting or Th2 cell-promoting dendritic cells in vitro with diverse the cell-polarizing signals. J. Immunol. 168 1704-1709.
20. Y.-H. Ding, B.M. Baker, D.N. Garboczi, W.E. Biddison and D.C. Wiley (1999) Four A6-TCR/peptide/HLA-A2 structures that generate very different T cell signals are nearly identical. Immunity 11 45-56.
21. R. Edelman (2002) The development and use of vaccine adjuvants. Mol. Biotechnol. 21 129-148.
22. J.H. Eldridge, J.K. Staas, Meulbroek, et al. (1991) Biodegradable microspheres as a vaccine delivery system. Mol. Immunol. 28 287-294.
23. H. Engers, M.P. Kieny, P. Malhotra, et al. (2003) Third meeting on novel adjuvants currently in or close to clinical testing Vaccine 21 3503-3524.
24. E. Espinosa, C. Belmant, F. Pont, et al. (2001) Chemical synthesis and biological activity of bromohydrin pyrophosphate, a potent stimulator of human gamma delta T cells. J. Biol. Chem. 276 18337-18344.
25. H. Groux, A. O'Garra, M. Bigler, M. Rouleau, S. Antonenko, J.E. de Vries and M.G. Roncarolo (1997) A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389 737-742.
26. H. Groux, N. Fournier and F. Cottrez (2004) Role of dendritic cells in the generation of regulatory T cells. Semin. Immunol. 16 99-106.
27. K. Haglund, I. Leiner, K. Kerksiek, et al. (2002) Robust recall and long-term memory T-cell responses induced by prime-boost regimens with heterologous live viral vectors expressing human immunodeficiency virus type 1 Gag and Env proteins. J. Virol. 76 7506-7517.
28. S.A. Hammond, D. Walwender, C.R. Alving and G. Glenn (2001) Transcutaneous immunization: T cell responses and boosting of existing immunity. Vaccine 19 2701-2707.
29. Y. Hayakawa, K. Takeda, H. Yagita, et al. (2001) Differential regulation of Th1 and Th2 functions of NKT cells by CD28 and CD40 costimulatory pathways. J. Immunol. 166 6012-6018.
30. H. Hemmi, T. Kaisho, O. Takeuchi, et al. (2002) Small antiviral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nature Immunol. 3 196-200.
31. S. Hori, T. Takahashi and S. Sakaguchi (2003) Control of autoimmunity by naturally arising regulatory CD4+T cells. Adv. Immunol. 81 331-371.
32. D.A. Horwitz, S.G. Zheng, J.D. Gray, J.H. Wang, K. Ohtsuka and S. Yamagiwa (2004) Regulatory T cells generated ex vivo as an approach for the therapy of autoimmune disease. Semin. Immunol. 16 135-143.
33. R.L. Hunter (2002) Overview of vaccine adjuvants: present and future. Vaccine 20 S7-S12.
34. A. Iwasaki and R. Medzhitov (2004) Toll-like receptor control of the adaptive immune responses. Nature Immunol. 5 987-995.
35. C.A. Janeway Jr. and R. Medzhitov (2002) Innate immune recognition. Annu. Rev. Immunol. 20 197-216.
36. H. Jonuleit and E. Schmitt (2003) The regulatory T cell family: distinct subsets and their interrelations. J. Immunol. 171 6323-6327.
37. H. Jonuleit and E. Schmitt (2005) Regulatory T-cells in antitumor therapy: isolation and functional testing of CD4+CD25+ regulatory T-cells. Methods Mol. Med. 109 285-296.
38. H. Jonuleit, E. Schmitt, K. Steinbrink and A.H. Enk (2001) Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol. 22 394-400.
39. H. Jonuleit, G. Adema and E. Schmitt (2003) Immune regulation by regulatory T cells: implications for transplantation. Transpl. Immunol. 11 267-276.
40. N. Kadowaki, S. Ho, S. Antonenko, et al. (2001) Subsets of human dendritic cell precursors express different Toll-like receptors and respond to different microbial antigens. J. Exp. Med. 194 863-869.
41. D.E. Katz, A.J. DeLorimier, M.K. Wolf, et al. (2003) Oral immunization of adult volunteers with microencapsulated enterotoxigenic Escherichia coli (ETEC) CS6 antigen. Vaccine 21 341-346.
42. C. Kemper, A.C. Chan, J.M. Green, K.A. Brett, K.M. Murphy and J.P. Atkinson (2003) Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature 421 388-392.
43. M. Klein (2001) Current progress in the development of human immunodeficiency virus vaccines: research and clinical trials. Vaccine 19 2210-2215.
44. A.M. Krieg (2002) CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20 709-730.
45. M. Kronenberg and L. Gapin (2002) The unconventional lifestyle of NKT cells. Nature Rev. Immunol. 2 557-568.
46. M.M. Levine and M.B. Sztein (2004) Vaccine development strategies for improving immunization: the role of modern immunology. Nature Immunol. 5 460-464.
47. M.K. Levings, R. Sangregorio, F. Galbiati, S. Squadrone, M.R. de Waal and M.G. Roncarolo (2001) IFN-alpha and IL-10 induce the differentiation of human type 1 T regulatory cells. J. Immunol. 166 5530-5539.
48. A. Lundgren, E. Suri-Payer, K. Enarsson, et al. (2003) Helicobacter pylori-specific CD4(+) CD25(high) regulatory T cells suppress memory T-cell responses to H. pylori in infected individuals. Infect. Immun. 71 1755-1762.
49. P. McGuirk, C. McCann and K.H. Mills (2002) Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis. J. Exp. Med. 195 221-231.
50. S. McSorley, C. Rask, R. Pichot, et al. (1998) Selective tolerization of Th1 like cells after nasal administration of a cholera toxoid-LACK antigen. Eur. J. Immunol. 28 424-430.
51. K.H. Mills and P. McGuirk (2004) Antigen-specific regulatory T cells: their induction and role in infection. Semin. Immunol. 16 107-117.
52. T. Mitchell, D. Hildeman, R. Keoll, et al. (2001) Immunological adjuvants promote activated T cell survival via induction of Bcl-3. Nature Immunol. 2 397-402.
53. P. Moingeon (2002) Strategies for designing vaccines eliciting Th1 responses in humans. J. Biotech. 98 189-198.
54. P. Moingeon, J. Haensler and A. Lindberg (2001) Towards the rational design of Th1 adjuvants. Vaccine 19 4363-4372.
55. P. Moingeon, C. De Taisne and J. Almond (2002) Delivery technologies for human vaccines. Br. Med. Bull. 62 29-44.
56. A.E. Morelli and A.W. Thomson (2003) Dendritic cells: regulators of alloimmunity and opportunities for tolerance induction. Immunol. Rev. 196 125-146.
57. T.R. Mosmann and S. Sad (1996) The expanding universe of T cell subsets: Th1, Th2 and more. Immunol. Today 17 138-146.
58. A.C. Mullen, F.A. High, A.S. Hutchins, H.W. Lee, A.V. Villarino, D.M. Livingston, A.L. King, N. Cereb, T-P Yao, S.Y. Yang and S.L. Reiner (2001) Role of T-bet in commitment of TH1 cells before IL-12-dependent selection. Science 292 195-199.
59. R. Offringa, S. van der burg, F. ossendorp, R. Toes and C. Melief (2000) Design and evaluation of antigen-specific vaccination strategies against cancer. Curr. Opin. Immunol. 12 576-582.
60. A. O'Garra and F.J. Barrat (2003) In vitro generation of IL-10-producing regulatory CD4+ T cells is induced by immunosuppressive drugs and inhibit by Th1- and Th2-inducing cytokines. Immunol. Lett. 85 135-139.
61. A. O'Garra and D. Robinson (2004) Development and function of T helper 1 cells. Adv. Immunol. 83 133-162.
62. A. O'Garra and P. Vieira (2004) Regulatory T cells and mechanisms of immune system control. Nature Med. 10 801-805.
63. D.T. O'Hagan and N.M. Valiante (2003) Recent advances in the discovery and delivery of vaccine adjuvants. Nature Rev. Drug Discov. 2 727-735.
64. M.R. Parkhurst, M.L. Salgaller, S. Southwood, P.F. Robbins, A. Sette, S.A. Rosenberg and Y. Kawakami (1996) Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J. Immunol. 157 2539-2548.
65. D.H. Persing, R.N. Coler, M.J. Lacy, et al. (2002) Taking toll: lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol. 10 S32-S37.
66. B. Pulendran (2004) Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol. Rev. 199 227-250.
67. B. Pulendran (2004) Modulating TH1/TH2 responses with microbes, dendritic cells, and pathogen recognition receptors. Immunol. Res. 29 187-196.
68. H.G. Rammensee, J. Bachman and S. Stevanovic (1997) MHC Ligands and Peptide Motifs Heidelberg: Springer Verlag
69. P.E. Rao, A.L. Petrone and P.D. Ponath (2005) Differentiation and expansion of T cells with regulatory function from human peripheral lymphocytes by stimulation in the presence of TGF-β. J. Immunol. 174 1446-1455.
70. E.L. Reinherz, K. Tan, L. Tang, P. Kern, J-H Liu, Y Xiong, R.E. Hussey, A. Smolyar, B. Hare, R. Zhang, A. Joachimiak, H-C Chang, G. Wagner and J.-H. Wang (1999) The crystal structure of a T cell receptor in complex with peptide and MHC class II. Science 286 1913-1917.
71. J. Rengarajan, S.J. Szabo and L.H. Glimcher (2000) Transcriptional regulation of Th1/Th2 polarization. Immunol. Today 21 478-486.
72. S. Romagnani (2004) The increased prevalence of allergy and the hygiene hypothesis: missing immune deviation, reduced immune suppression, or both? Immunology 112 352-363.
73. S. Rutella and R.M. Lemoli (2004) Regulatory T cells and tolerogenic dendritic cells: from basic biology to clinical applications. Immunol. Lett. 94 11-26.
74. S. Sakaguchi (2003) Control of immune responses by naturally arising CD4+ regulatory T cells that express toll-like receptors. J. Exp. Med. 197 397-401.
75. S. Sakaguchi (2004) Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22 531-562.
76. A. Saul, G. Lawrence, A. Smillie, et al. (1999) Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant. Vaccine 17 3145-3159.
77. F. Sallusto, J. Geginat and A. Lanzavecchia (2004) Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol. 22 745-763.
78. V. Schijns (2000) Immunological concepts of vaccine adjuvant activity. Curr. Opin. Immunol. 12 456-463.
79. K.S. Schluns and L. Lefrancois (2003) Cytokine control of memory T-cell development and survival. Nature Rev. Immunol. 3 269-279.
80. G. Sireci, E. Espinosa, C. Di Sano, et al. (2001) Differential activation of human gamma delta cells by nonpeptide phosphoantigens. Eur. J. Immunol. 31 1628-1635.
81. M. Stassen, E. Schmitt and H. Jonuleit (2004) Human CD(4+)CD(25+) regulatory T cells and infectious tolerance. Transplantation 77 S23-S25.
82. M. Stassen, H. Jonuleit, C. Muller, M. Klein, C. Richter, T. Bopp, S. Schmitt and E. Schmitt (2004) Differential regulatory capacity of CD25+ T regulatory cells and preactivated CD25+ T regulatory cells on development, functional activation, and proliferation of Th2 cells. J. Immunol. 173 267-274.
83. P. Stock, O. Akbari, G. Berry, G.J. Freeman, R.H. DeKruyff and D.T. Umetsu (2004) Induction of T helper type 1-like regulatory cells that express Foxp3 and protect against airway hyper-reactivity. Nature Immunol. 5 1149-1156.
84. J.B. Sun, J. Holmgren and C. Czerkinsky (1994) Cholera toxin B subunit: an efficient transmucosal delivery system for induction of peripheral immunological tolerance. Proc. Natl. Acad. Sci. USA 91 10795-10800.
85. K. Takeda, T. Kaisho and S. Akira (2003) Toll-like receptors. Annu. Rev. Immunol. 21 335-376.
86. J. Tartaglia, J.L. Excler, R. ElHabib, K. Limbach, B. Meignier, S. Plotkin and M. Klein (1998) Canary pox virus-based vaccines: prime-boost strategies to induce cell-mediated and humoral immunity against HIV. AIDS Res. Hum. Retroviruses 14 S291-S298.
87. A. Taylor, J. Verhagen, C.A. Akdis and M. Akdis (2004) T regulatory cells in allergy and health: a question of allergen specificity and balance. Int. Arch. Allergy Immunol. 135 73-82.
88. C. Thompson and F. Powrie (2004) Regulatory T cells. Curr. Opin. Pharmacol. 4 408-414.
89. J. Tine, H. Firat, A. Payne, G. Russo, S.W. Davis, J. Tartaglia, F. Lemonnier, P. Langlade-Demoyen and P. Moingeon (2005) Enhanced multiepitope vaccines elicit CD8+ cytoxic T cells against both immunodominant and crytic epitopes. Vaccine 23 1085-1091.
90. F.R. Vogel (2000) Improving vaccine performance with adjuvants. Clin. Infect. Dis. 30(Suppl. 3), S266-S270.
91. S.H. Van der Burg, M.J. Visseren, R.M. Brandt, W.M. Kast and C.J. Melief (1996) Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J. Immunol. 156 3308-3314.
92. M. Von Herrath and D. Homann (2003) Introducing baselines for therapeutic use of regulatory T cells and cytokines in autoimmunity. Trends Immunol. 24 540-545.
93. E.J. Wherry, V. Teichgraber, T.C. Becker, et al. (2003) Lineage relationship and protective immunity of memory CD8 T cell subsets. Nature Immunol. 4 225-234.
94. K.J. Wood and S. Sakaguchi (2003) Regulatory T cells in transplantation tolerance. Nature Rev. Immunol. 3 199-210.
95. S. Yamagiwa, J.D. Gray, S. Hashimoto and D.A. Horwitz (2001) A role for TGF-beta in the generation and expansion of CD4+CD25+ regulatory T cells from human peripheral blood. J. Immunol. 166 7282-7289.
96. S. Zaremba, E. Barzaga, M. Zhu, N. Soares, K.-Y. Tsang and J. Schlom (1997) Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res. 57 4570-4577.
97. S.A. Hammond, D. Walwender, C.R. Alving and G.M. Glenn (2001) Transcutaneous immunization: T cell responses and boosting of existing immunity. Vaccine 19 2701-2707.
98. J. Holmgren (1973) Comparison of the tissue receptors for Vibrio cholerae and Escherichia coli enterotoxins by means of gangliosides and natural cholera toxoid. Infect. Immun. 8 851-859.
99. J. Holmgren, C. Czerkinsky, K. Eriksson and A. Mharandi (2003) Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges. Vaccine 21(Suppl. 2), S89-S95.
100. A.D. Horne, J. Clifford, K.L. Goldenthal, C. Kleppinger and P.A. Lachenbruch (2004) Preventive vaccines against bioterrorism: evaluation of efficacy and safety. Vaccine 23 84-90.
101. M. Huerta, I. Grotto, M. Gdalevich, D. Mimouni, B. Gavrieli, M. Yavzori, D. Cohen and O. Shpilberg (2000) A waterborne outbreak of gastroenteritis in the Golan Heights due to enterotoxigenic Escherichia coli. Infection 28 267-271.
102. M. John, E.A. Bridges, A.O. Miller, S.B. Calderwood and E.T. Ryan (2002) Comparison of mucosal and systemic humoral immune responses after transcutaneous and oral immunization strategies. Vaccine 20 2720-2726.
103. R. Kahlon, Y. Hu, C.H. Orteu, A. Kifayet, J.D. Trudeau, R. Tan and J.P. Dutz (2003) Optimization of epicutaneous immunization for the induction of CTL. Vaccine 21 2890-2899.
104. R. Kenney, J. Yu, M. Guebre-Xabier, A. Lambert, B. Heller, L. Ellingsworth, J. Eyles, E.D. Williamson and G. Glenn (2004) Induction of protective immunity against lethal anthrax challenge with a patch. J. Infect. Dis. 190 774-782.
105. R.T. Kenney and R. Edelman (2004) M.M. Levine,(Ed.) New Generation Vaccines 3rd edn. New York: Marcel Dekker 213-223.
106. K.L. Kotloff, M.B. Sztein, S.S. Wasserman, G.A. Losonsky, S.C. DiLorenzo and R.I. Walker (2001) Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect. Immun. 69 3581-3590.
107. G.M. Kuziemko, M. Stroh and R.C. Stevens (1996) Cholera toxin binding affinity and specificity for gangliosides determined by surface plasmon resonance. Biochemistry 35 6375-6384.
108. W.I. Lencer, C. Constable, S. Moe, M.G. Jobling, H.M. Webb, S. Ruston, J.L. Madara, T.R. Hirst and R.K. Holmes (1995) Targeting of cholera toxin and Escherichia coli heat labile toxin in polarized epithelia: role of COOH-terminal KDEL. J. Cell Biol. 131 951-962.
109. N. Lycke (1997) The mechanism of cholera toxin adjuvanticity. Res. Immunol. 148 504-520.
110. N. Lycke, T. Tsuji and J. Holmgren (1992) The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur. J. Immunol. 22 2277-2281.
111. C.R. MacKenzie, T. Hirama, K.K. Lee, E. Altman and N.M. Young (1997) Quantitative analysis of bacterial toxin affinity and specificity for glycolipid receptors by surface plasmon resonance. J. Biol. Chem. 272 5533-5538.
112. I. Majoul, K. Sohn, F.T. Wieland, R. Pepperkok, M. Pizza, J. Hillemann and H.D. Soling (1998) KDEL receptor (Erd2p)-mediated retrograde transport of the cholera toxin A subunit from the Golgi involves COPI, p23, and the COOH terminus of Erd2p. J. Cell Biol. 143 601-612.
113. I.V. Majoul, P.I. Bastiaens and H.D. Soling (1996) Transport of an external Lys-Asp-Glu-Leu (KDEL) protein from the plasma membrane to the endoplasmic reticulum: studies with cholera toxin in Vero cells. J. Cell Biol. 133 777-789.
114. P.C. Marchisio, S. Bondanza, O. Cremona, R. Cancedda and M. De Luca (1991) Polarized expression of integrin receptors (alpha 6 beta 4, alpha 2 beta 1, alpha 3 beta 1, and alpha v beta 5) and their relationship with the cytoskeleton and basement membrane matrix in cultured human keratinocytes. J. Cell Biol. 112 761-773.
115. M. Martin, A. Sharpe, J.D. Clements and S.M. Michalek (2002) Role of B7 costimulatory molecules in the adjuvant activity of the heat-labile enterotoxin of Escherichia coli. J. Immunol. 169 1744-1752.
116. M.P. Matousek, J.G. Nedrud, W. Cieplak Jr. and C.V. Harding (1998) Inhibition of class II major histocompatibility complex antigen processing by Escherichia coli heat-labile enterotoxin requires an enzymatically active A subunit. Infect. Immun. 66 3480-3484.
117. J.A. Matriano, M. Cormier, J. Johnson, W.A. Young, M. Buttery, K. Nyam and P.E. Daddona (2002) Macroflux microprojection array patch technology: a new and efficient approach for intracutaneous immunization. Pharm. Res. 19 63-70.
118. J.J. Mekalanos, R.J. Collier and W.R. Romig (1979) Enzymic activity of cholera toxin: II. Relationships to proteolytic processing, disulfide bond reduction, and subunit composition. J. Biol. Chem. 254 5855-5861.
119. P. Michetti, C. Kreiss, K.L. Kotloff, N. Porta, J.L. Blanco, D. Bachmann, M. Herranz, P.F. Saldinger, I. Corthesy-Theulaz, G. Losonsky, R. Nichols, J. Simon, M. Stolte, S. Ackerman, T.P. Monath and A.L. Blum (1999) Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology 116 804-812.
120. J.A. Mikszta, J.B. Alarcon, J.M. Brittingham, D.E. Sutter, R.J. Pettis and N.G. Harvey (2002) Improved genetic immunization via micromechanical disruption of skinbarrier function and targeted epidermal delivery. Nature Med. 8 415-419.
121. J.A. Mikszta, V.J. Sullivan, C. Dean, A.M. Waterston, J.B. Alarcon, J.P. Dekker 3rd, J.M. Brittingham, J. Huang, C.R. Hwang, M. Ferriter, G. Jiang, K. Mar, K.U. Saikh, B.G. Stiles, C.J. Roy, R.G. Ulrich and N.G. Harvey (2005) Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms. J. Infect. Dis. 191 278-288.
122. D.G. Millar and T.R. Hirst (2001) Cholera toxin and Escherichia coli enterotoxin B-subunits inhibit macrophage-mediated antigen processing and presentation: evidence for antigen persistence in non-acidic recycling endosomal compartments. Cell Microbiol. 3 311-329.
123. A. Misra, S. Ganga and P. Upadhyay (1999) Needle-free, non-adjuvanted skin immunization by electroporation-enhanced transdermal delivery of diphtheria toxoid and a candidate peptide vaccine against hepatitis B virus. Vaccine 18 517-523.
124. S. Mitragotri, D. Blankschtein and R. Langer (1995) Ultrasound-mediated transdermal protein delivery. Science 269 850-853.
125. R. Moll, W.W. Franke, D.L. Schiller, B. Geiger and R. Krepler (1982) The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 31 11-24.
126. R. Montesano, J. Roth, A. Robert and L. Orci (1982) Non-coated membrane invaginations are involved in binding and internalization of cholera and tetanus toxins. Nature 296 651-653.
127. P. Morganti, E. Ruocco, R. Wolf and V. Ruocco (2001) Percutaneous absorption and delivery systems. Clin. Dermatol. 19 489-501.
128. J. Moss, J.C. Osborne Jr., P.H. Fishman, H.B. Brewer Jr., M. Vaughan and R.O. Brady (1977) Effect of gangliosides and substrate analogues on the hydrolysis of nicotinamide adenine dinucleotide by choleragen. Proc. Natl. Acad. Sci. USA 74 74-78.
129. D.M. Murasko, E.D. Bernstein, E.M. Gardner, P. Gross, G. Munk, S. Dran and E. Abrutyn (2002) Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly. Exp. Gerontol. 37 427-439.
130. M. Mutsch, W. Zhou, P. Rhodes, M. Bopp, R.T. Chen, T. Linder, C. Spyr and R. Steffen (2004) Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 350 896-903.
131. C.J. O'Neal, E.I. Amaya, M.G. Jobling, R.K. Holmes and W.G. Hol (2004) Crystal structures of an intrinsically active cholera toxin mutant yield insight into the toxin activation mechanism. Biochemistry 43 3772-3782.
132. L. Ohl, M. Mohaupt, N. Czeloth, G. Hintzen, Z. Kiafard, J. Zwirner, T. Blankenstein, G. Henning and R. Forster (2004) CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions. Immunity 21 279-288.
133. T. Okada, H. Konishi, M. Ito, H. Nagura and J. Asai (1988) Identification of secretory immunoglobulin A in human sweat and sweat glands. J. Invest. Dermatol. 90 648-651.
134. W.L. Olszewski, I. Grzelak, A. Ziolkowska and A. Engeset (1995) Immune cell traffic from blood through the normal human skin to lymphatics. Clin. Dermatol. 13 473-483.
135. P.A. Orlandi and P.H. Fishman (1998) Filipin-dependent inhibition of cholera toxin: evidence for toxin internalization and activation through caveolae-like domains. J. Cell Biol. 141 905-915.
136. J.E. Osorio, C.L. Zuleger, M. Burger, Q. Chu, L.G. Payne and D. Chen (2003) Immune responses to hepatitis B surface antigen following epidermal powder immunization. Immunol. Cell Biol. 81 52-58.
137. C.D. Partidos (2003) Delivering vaccines into the skin without needles and syringes. Expert Rev. Vaccines 2 753-761.
138. R.G. Parton (1994) Ultrastructural localization of gangliosides; GM1 is concentrated in caveolae. J. Histochem. Cytochem. 42 155-166.
139. R.G. Parton and A.A. Richards (2003) Lipid rafts and caveolae as portals for endocytosis: new insights and common mechanisms. Traffic 4 724-738.
140. T. Pentcheva-Hoang, J.G. Egen, K. Wojnoonski and J.P. Allison (2004) B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity 21 401-413.
141. L. Petrovska, L. Lopes, C.P. Simmons, M. Pizza, G. Dougan and B.M. Chain (2003) Modulation of dendritic cell endocytosis and antigen processing pathways by Escherichia coli heat-labile enterotoxin and mutant derivatives. Vaccine 21 1445-1454.
142. M.R. Prausnitz, V.G. Bose, R. Langer and J.C. Weaver (1993) Electroporation of mammalian skin: a mechanism to enhance transdermal drug delivery. Proc. Natl. Acad. Sci. USA 90 10504-10508.
143. M.R. Prausnitz, J.A. Gimm, R.H. Guy, R. Langer, J.C. Weaver and C. Cullander (1996) Imaging regions of transport across human stratum corneum during high-voltage and low-voltage exposures. J. Pharm. Sci. 85 1363-1370.
144. C.M. Richards, A.T. Aman, T.R. Hirst, T.J. Hill and N.A. Williams (2001) Protective mucosal immunity to ocular herpes simplex virus type 1 infection in mice by using Escherichia coli heat-labile enterotoxin B subunit as an adjuvant. J. Virol. 75 1664-1671.
145. S.H. Richardson, J.C. Giles and K.S. Kruger (1984) Sealed adult mice: new model for enterotoxin evaluation. Infect. Immun. 43 482-486.
146. M.S. Roberts and M. Walker (1993) Water, the Most Natural Penetration Enhancer New York: Marcel Dekker
147. S.T. Rottinghaus, G.A. Poland, R.M. Jacobson, L.J. Barr and M.J. Roy (2003) Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination. Vaccine 21 4604-4608.
148. M.J. Roy, M.S. Wu, L.J. Barr, J.T. Fuller, L.G. Tussey, S. Speller, J. Culp, J.K. Burkholder, W.F. Swain, R.M. Dixon, G. Widera, R. Vessey, A. King, G. Ogg, A. Gallimore, J.R. Haynes and D. Heydenburg Fuller (2000) Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particlemediated administration of a hepatitis B virus DNA vaccine. Vaccine 19 764-778.
149. E.J. Ryan, E. McNeela, M. Pizza, R. Rappuoli, L. O'Neill and K.H. Mills (2000) Modulation of innate and acquired immune responses by Escherichia coli heat-labile toxin: distinct pro- and anti-inflammatory effects of the nontoxic AB complex and the enzyme activity. J. Immunol. 165 5750-5759.
150. M. Sandkvist, M. Bagdasarian and S.P. Howard (2000) Characterization of the multimeric Eps complex required for cholera toxin secretion. Int. J. Med. Microbiol. 290 345-350.
151. T. Scharton-Kersten, J. Yu, R. Vassell, D. O'Hagan, C.R. Alving and G.M. Glenn (2000) Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants. Infect. Immun. 68 5306-5313.
152. R. Schirmbeck, W. Bohm, K. Ando, F.V. Chisari and J. Reimann (1995) Nucleic acid vaccination primes hepatitis B virus surface antigen-specific cytotoxic T lymphocytes in nonresponder mice. J. Virol. 69 5929-5934.
153. A. Schmitz, H. Herrgen, A. Winkeler and V. Herzog (2000) Cholera toxin is exported from microsomes by the Sec61p complex. J. Cell Biol. 148 1203-1212.
154. N. Seo, F. Furukawa, Y. Tokura and M. Takigawa (2003) Vaccine therapy for cutaneous T-cell lymphoma. Hematol. Oncol. Clin. North Am. 17 1467-1474.
155. G.W. Sharp and S. Hynie (1971) Stimulation of intestinal adenyl cyclase by cholera toxin. Nature 229 266-269.
156. C.P. Simmons, M. Ghaem-Magami, L. Petrovska, L. Lopes, B.M. Chain, N.A. Williams and G. Dougan (2001) Immunomodulation using bacterial enterotoxins. Scand. J. Immunol. 53 218-226.
157. M. Singh and D. O'Hagan (1999) Advances in vaccine adjuvants. Nature Biotechnol. 17 1075-1081.
158. T.K. Sixma, S.E. Pronk, K.H. Kalk, E.S. Wartna, B.A. van Zanten, B. Witholt and W.G. Hol (1991) Crystal structure of a cholera toxin-related heat-labile enterotoxin from. E. coli Nature 351 371-377.
159. T.K. Sixma, S.E. Pronk, K.H. Kalk, B.A. van Zanten, A.M. Berghuis and W.G. Hol (1992) Lactose binding to heat-labile enterotoxin revealed by X-ray crystallography. Nature 355 561-564.
160. T.K. Sixma, K.H. Kalk, B.A. van Zanten, Z. Dauter, J. Kingma, B. Witholt and W.G. Hol (1993) Refined structure of Escherichia coli heat-labile enterotoxin, a close relative of cholera toxin. J. Mol. Biol. 230 890-918.
161. D.P. Snider (1995) The mucosal adjuvant activities of ADP-ribosylating bacterial enterotoxins. Crit. Rev. Immunol. 15 317-348.
162. B.D. Spangler (1992) Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol. Rev. 56 622-647.
163. H. Steinsland, P. Valentiner-Branth, H.K. Gjessing, P. Aaby, K. Molbak and H. Sommerfelt (2003) Protection from natural infections with enterotoxigenic Escherichia coli: longitudinal study. Lancet 362 286-291.
164. M. Tauschek, R.J. Gorrell, R.A. Strugnell and R.M. Robins-Browne (2002) Identification of a protein secretory pathway for the secretion of heat-labile enterotoxin by an enterotoxigenic strain of Escherichia coli. Proc. Natl. Acad. Sci. USA 99 7066-7071.
165. K. Teter, M.G. Jobling and R.K. Holmes (2003) A class of mutant CHO cells resistant to cholera toxin rapidly degrades the catalytic polypeptide of cholera toxin and exhibits increased endoplasmic reticulum-associated degration. Traffic 4 232-242.
166. S.M. Thacher and R.H. Rice (1985) Keratinocyte-specific transglutaminase of cultured human epidermal cells: relation to cross-linked envelope formation and terminal differentiation. Cell 40 685-695.
167. R. Tierney, A.S. Beignon, R. Rappuoli, S. Muller, D. Sesardic and C.D. Partidos (2003) Transcutaneous immunization with tetanus toxoid and mutants of Escherichia coli heat-labile enterotoxin as adjuvants elicits strong protective antibody responses. J. Infect. Dis. 188 753-758.
168. E.C. Todd (1997) Epidemiology of foodborne diseases: a worldwide review. World Health Stat. Q. 50 30-50.
169. V. Turcanu, T.R. Hirst and N.A. Williams (2002) Modulation of human monocytes by Escherichia coli heat-labile enterotoxin B-subunit; altered cytokine production and its functional consequences. Immunology 106 316-325.
170. P. Van Damme, R. Vranckx, A. Safary, F.E. Andre and A. Meheus (1989) Protective efficacy of a recombinant deoxyribonucleic acid hepatitis B vaccine in institutionalized mentally handicapped clients. Am. J. Med. 87 26S-29S.
171. R. Vanbever, N. Lecouturier and V. Preat (1994) Transdermal delivery of metoprolol by electroporation. Pharm. Res. 11 1657-1662.
172. B. Wang, L. Zhuang, H. Fujisawa, G.A. Shinder, C. Feliciani, G.M. Shivji, H. Suzuki, P. Amerio, P. Toto and D.N. Sauder (1999) Enhanced epidermal Langerhans cell migration in IL-10 knockout mice. J. Immunol. 162 277-283.
173. C. Watts and S. Amigorena (2000) Antigen traffic pathways in dendritic cells. Traffic 1 312-317.
174. L.J. Weimann and J. Wu (2002) Transdermal delivery of poly-1-lysine by sonomacroporation. Ultrasound Med. Biol. 28 1173-1180.
175. D.J. West (1989) Clinical experience with hepatitis B vaccines. Am. J. Infect. Control 17 172-180.
176. N.A. Williams, L.M. Stasiuk, T.O. Nashar, C.M. Richards, A.K. Lang, M.J. Day and T.R. Hirst (1997) Prevention of autoimmune disease due to lymphocyte modulation by the B-subunit of Escherichia coli heat-labile enterotoxin. Proc. Natl. Acad. Sci. USA 94 5290-5295.
177. J.M. Wilson, M. de Hoop, N. Zorzi, B.H. Toh, C.G. Dotti and R.G. Parton (2000) EEA1, a tethering protein of the early sorting endosome, shows a polarized distribution in hippocampal neurons, epithelial cells, and fibroblasts. Mol. Biol. Cell 11 2657-2671.
178. A.A. Wolf, M.G. Jobling, S. Wimer-Mackin, M. Ferguson-Maltzman, J.L. Madara, R.K. Holmes and W.I. Lencer (1998) Ganglioside structure dictates signal transduction by cholera toxin and association with caveolae-like membrane domains in polarized epithelia. J. Cell Biol. 141 917-927.
179. A. Yoshida, T. Nagata, M. Uchijima, T. Higashi and Y. Koide (2000) Advantage of gene gun-mediated over intramuscular inoculation of plasmid DNA vaccine in reproducible induction of specific immune responses. Vaccine 18 1725-1729.
180. J. Yu, F. Cassels, T. Scharton-Kersten, S.A. Hammond, A. Hartman, E. Angov, B. Corthesy, C. Alving and G. Glenn (2002) Transcutaneous immunization using colonization factor and heat-labile, enterotoxin induces correlates of protective immunity for enterotoxigenic Escherichia coli. Infect. Immun. 70 1056-1068.
181. R.C. Yu, D.C. Abrams, M. Alaibac and A.C. Chu (1994) Morphological and quantitative analyses of normal epidermal Langerhans cells using confocal scanning laser microscopy. Br. J. Dermatol. 131 843-848.
182. T.E. Zewert, U.F. Pliquett, R. Langer and J.C. Weaver (1995) Transdermal transport of DNA antisense oligonucleotides by electroporation. Biochem. Biophys. Res. Commun. 212 286-292.
183. T.E. Zewert, U.F. Pliquett, R. Vanbever, R. Langer and J.C. Weaver (1999) Creation of transdermal pathways for macromolecule transport by skin electroporation and a low toxicity, pathway-enlarging molecule. Bioelectrochem. Bioenerg. 49 11-20.
184. L. Zhang, E. Nolan, S. Kreitschitz and D.P. Rabussay (2002) Enhanced delivery of naked DNA to the skin by non-invasive in vivo electroporation. Biochim. Biophys. Acta 1572 1-9.
185. R. Zurbriggen, I.C. Metcalfe, R. Gluck, J.F. Viret and C. Moser (2003) Nonclinical safety evaluation of Escherichia coli heat-labile toxin mucosal adjuvant as a component of a nasal influenza vaccine. Expert Rev. Vaccines 2